Schrodinger Inc (SDGR) Fair Value & Analysis
Healthcare · US · Market cap $1.1B · ISIN US80810D1037
What is Schrodinger Inc really worth?
Schrodinger Inc
SDGR · US
A solid business, but trading 379% above our fair value of $4.32.
Strengths
Risks
Fair value as of: Sep 2, 2026
From 7 valuation models · updated 2 days ago
Share price +32.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case ($5.06). The favourable scenario is already priced in.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 2, 2026.
How to read this chart
60‑month range $11.07 – $78.80 · fair‑value band $3.58 – $5.06 · the $20.71 price screens above the $4.32 fair value. Dashed = 300-day average. As of Sep 2, 2026.
Analysis
Schrodinger Inc (SDGR) currently trades at $20.71, while our model-based Fair Value estimate is $4.32, implying the stock looks roughly 379.4% overvalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: the Growth DCF group reads highest at a median of $7.32 per share, and 0 of the 7 models we run sit above the $20.71 price. Bear case: the Asset-Based group reads lowest at $3.72, and 7 of the 7 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, Schrodinger Inc generated revenue of $255M at a net margin of −40.6%. Revenue declined 1.6% year over year. It earns a return on equity of −30.1%. The balance sheet holds a net cash position of $121M. Fundamentals as of Sep 2, 2026
Our scenario range runs from $3.58 (bear case) to $5.06 (bull case); at $20.71, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 13% below its 52-week high and 89% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −68% fair-value upside, at −79%, SDGR screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 7 models by family
Widest divergence: Growth DCF ($7.32) versus Asset-Based ($3.72). Highest evidence: FCF DCF (79).
Notify me when SDGR reaches fair value
Put SDGR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 2, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 49
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery.
Full company description
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Schrodinger Inc reported revenue of $256M in FY2025 versus $138M in FY2021, a compound +16.7%/yr. Reported net income was −$103M in FY2025.
SDGR screens 379% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 128 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Sep 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $282.13 | $91.49 | −68% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | −87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | −64% |
| HealthEquity, Inc HQY | $104.27 | $56.63 | −46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | −72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | −69% |
| Waystar Holding WAY | $25.76 | $12.86 | −50% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | −87% |
| Doximity, Inc DOCS | $24.74 | $25.91 | +5% |
| Privia Health Group PRVA | $21.07 | $5.26 | −75% |
Compare Schrodinger Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Schrodinger Inc (SDGR) overvalued or undervalued?
What is the fair value of SDGR?
What is the quality score of SDGR?
What is the revenue of Schrodinger Inc (SDGR)?
What is the net profit margin of SDGR?
Watch Schrodinger Inc in the live analysis
One click puts Schrodinger Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.